Phaseline

Companies › Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical: clinical trials, targets and expected readouts

16 active drug programs in 31 registered trials: 15 Phase 1, 10 Phase 2, 6 Phase 3; Oncology, Immunology, Hematology, Gastroenterology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TQB2102 for injection
HER2-targeting antibody-drug conjugate (ADC) with dual epitope targeting (ECD2 and ECD4)
ERBB2Phase 3HER2-positive Breast Cancer; Metastatic Breast Cancer; Breast Cancer; Gynecological Tumors …Nov 2026
TQB2930 injection
Dual-epitope HER2 antibody targeting ECD2 and ECD4 epitopes
ERBB2Phase 3HER2-positive Advanced Breast Cancer; Colorectal Cancer; Advanced Solid TumorJun 2027
TQH3906 Capsules
Highly selective TYK2 allosteric inhibitor targeting the JH2 domain, blocking IL-23 and Ty
TYK2Phase 3Psoriasis; Psoriatic Arthritis; Inflammatory Bowel DiseasesJul 2027
Recombinant human coagulation factor VIII for injection
Recombinant human coagulation factor VIII (replacement therapy)
F8Phase 3Hemophilia A–
TQB2868 injection
Anti-PD-1/TGF-βRII bifunctional fusion protein
PDCD1, TGFBR2Phase 2Pancreatic NeoplasmsNov 2026
Benmelstobart injection
Humanized monoclonal antibody targeting PD-L1
CD274Phase 2Non-Small Cell Lung CancerDec 2026
TQA2225/AP025
FGF21-Fc fusion protein
FGF21Phase 2Non-alcoholic SteatohepatitisDec 2026
TQC2938
humanized monoclonal antibody interfering with signal cascade
–Phase 2Chronic Obstructive Pulmonary DiseaseMar 2027
TQB2916 Injection–Phase 2Pancreatic CancerAug 2027
TQB2922 for injection
anti-EGFR/c-Met bispecific antibody
EGFR, METPhase 1Advanced Cancer; RAS/BRAF Wild Type Colorectal CancerDec 2026
TQB2934
Anti-CD3 × BCMA double-specific antibody (bispecific T-cell engager)
CD3, BCMAPhase 1Multiple MyelomaOct 2027
TQB6411 injection
EGFR/c-Met dual-targeting antibody-drug conjugate (ADC)
EGFR, METPhase 1Advanced Malignant TumorsDec 2027
TQB2029 for injection
bispecific antibody targeting GPRC5D and CD3; recruits and activates CD3+ T cells to kill
GPRC5D, CD3Phase 1Multiple MyelomaMar 2028
TQB2101 for Injection
anti-ROR1 antibody-drug conjugate
ROR1Phase 1Advanced Hematologic MalignanciesJun 2028
LM-108 injection
Monoclonal antibody that selectively depletes regulatory T cells infiltrating tumor sites
–Phase 1Advanced Solid Tumor–
TQH2929 Injection
humanized monoclonal antibody interfering with signal cascade
–Phase 1Generalized Pustular Psoriasis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06433531TQH2929 InjectionPhase 1Generalized Pustular PsoriasisImmunologyJul 2025
NCT06825494LM-108 injectionPhase 1Advanced Solid TumorOncologyMar 2026
NCT06297655Recombinant human coagulation factor VIII for injectionPhase 3Hemophilia AHematologyJul 2026
NCT06767813TQB2868 injectionPhase 2Pancreatic NeoplasmsOncologyNov 2026
NCT06798207TQB2102 for injectionPhase 2Gynecological TumorsOncologyNov 2026
NCT06188624TQB2922 for injectionPhase 1Advanced CancerOncologyDec 2026
NCT06569524TQA2225/AP025Phase 2Non-alcoholic SteatohepatitisGastroenterologyDec 2026
NCT06496490Benmelstobart injectionPhase 2Non-Small Cell Lung CancerOncologyDec 2026
NCT06496490TQB2102 for injectionPhase 2Non-Small Cell Lung CancerOncologyDec 2026
NCT06789289TQC2938Phase 2Chronic Obstructive Pulmonary DiseaseRespiratoryMar 2027
NCT06431490TQB2102 for injectionPhase 1Biliary Tract CancerOncologyMay 2027
NCT07653685TQB2930 injectionPhase 1Colorectal CancerOncologyJun 2027
NCT07044908TQB2922 for injectionPhase 1RAS/BRAF Wild Type Colorectal CancerOncologyJul 2027
NCT07044908TQB2922 for injectionPhase 1RAS/BRAF Wild Type Colorectal CancerOncologyJul 2027
NCT06754891TQH3906 CapsulesPhase 1Inflammatory Bowel DiseasesImmunologyJul 2027
NCT05735496TQB2102 for injectionPhase 1Advanced CancerOncologyJul 2027
NCT07406035TQH3906 CapsulesPhase 2Psoriatic ArthritisImmunologyAug 2027
NCT06962267TQB2916 InjectionPhase 2Pancreatic CancerOncologyAug 2027
NCT07724366TQH3906 CapsulesPhase 3PsoriasisImmunologySep 2027
NCT07043725TQB2102 for injectionPhase 3HER2-positive Breast CancerOncologySep 2027
NCT06767800TQB2102 for injectionPhase 2Gastroesophageal AdenocarcinomaOncologySep 2027
NCT07179679TQB2934Phase 1Multiple MyelomaOncologyOct 2027
NCT07043751TQB6411 injectionPhase 1Advanced Malignant TumorsOncologyDec 2027
NCT06700395TQB2029 for injectionPhase 1Multiple MyelomaOncologyMar 2028
NCT07008976TQB2102 for injectionPhase 3Metastatic Breast CancerOncologyMar 2028
NCT07512583TQB2930 injectionPhase 1Advanced Solid TumorOncologyMar 2028
NCT07512583TQB2930 injectionPhase 1Advanced Solid TumorOncologyMar 2028
NCT07113925TQB2101 for InjectionPhase 1Advanced Hematologic MalignanciesOncologyJun 2028
NCT06452706TQB2102 for injectionPhase 2Breast CancerOncologyJun 2028
NCT07047365TQB2930 injectionPhase 3HER2-positive Advanced Breast CancerOncologyJun 2028
NCT07003074TQB2102 for injectionPhase 3Breast CancerOncologyJul 2029

Targets

EGFR (2) MET (2) CD3 (2) ERBB2 (2) BCMA (1) TYK2 (1) F8 (1) ROR1 (1) FGF21 (1) CD274 (1) PDCD1 (1) TGFBR2 (1)

Companies with the same targets

AstraZeneca Beijing Biotech Shanghai Henlius Biotech Chia Tai Tianqing Pharmaceutical Group Johnson & Johnson (Janssen) AbbVie Pfizer Roche Yuhan Betta Pharmaceuticals

Companies built like this

Shanghai Henlius Biotech Sichuan Baili Pharmaceutical Sichuan Kelun-Biotech Biopharmaceutical Merck KGaA Shenyang Sunshine Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.